We have launched our mobile app, get it now. Call : 9354229384, 9354252518, 9999830584.  

Tags Current Affairs

Pfizer vaccine

Date: 23 August 2020 Tags: Biotechnology

Issue

US Pharma giant Pfizer and German biotechnology company BioNTech’s, which are testing four vaccine candidates for Covid-19 as part of Project Lightspeed, released the phase-1 data for one of these, being tested in the US.

 

Background

The study said that across all populations, the candidate was well-tolerated and demonstrated a strong immune response, and that they are on track to seek regulatory review in October 2020.

 

Details

  • The project with four vaccine candidates is based on BionTech’s proprietary mRNA-based technology platforms. It began in mid-January after the genetic sequence of SARS-CoV-2 was made public.

  • Two of these four candidates — BNT162b1 or BNT162b2 — have gone into human trials so far. Both are in Phase 1/2 human trials in the United States and Germany.

  • The researchers announced that after extensive review of preclinical and clinical data and in consultation with the US FDA’s Center for Biologics Evaluation and Research, they have chosen to advance their BNT162b2 vaccine candidate into the Phase 2/3 study, where 30,000 participants will be taking part.

 

  BNT162b2

  • It is a single nucleoside-modified messenger RNA (modRNA) vaccine candidate. It is made of a short segment of genetic material — the messenger RNA — which provides instructions for a human cell to make a harmless version of a target protein, in this case the spike protein of SARS-CoV-2, in order to activate an immune response against the protein.

  • During a clinical trial, three aspects are assessed: reactogenicity (ability to produce common, adverse reactions), immunogenicity (ability to provoke an immune response), and safety.

  • BNT162b2 was associated with less systemic reactogenicity, particularly in older adults. This effectively means that BNT162b2 generates an even lower adverse reaction among the vulnerable population, making it the safer candidate of the two.

Notice (8): Undefined variable: quizpole [ROOT/plugins/Studyiq/src/Template/Pages/tagdetails.ctp, line 161]